Rest perfusion abnormalities in hypertrophic cardiomyopathy: correlation with myocardial fibrosis and risk factors for sudden cardiac death  by Chiribiri, A. et al.
lable at ScienceDirect
Clinical Radiology 70 (2015) 495e501Contents lists avaiClinical Radiology
journal homepage: www.cl inicalradiologyonl ine.netRest perfusion abnormalities in hypertrophic
cardiomyopathy: correlation with myocardial
ﬁbrosis and risk factors for sudden cardiac death
A. Chiribiri a,b,*, S. Leuzzi c, M.R. Conte d, S. Bongioanni d, K. Bratis a,
L. Olivotti a,e, C. De Rosa d, E. Lardone d, P. Di Donna c, A.D.M. Villa a,
F. Cesarani f, E. Nagel a, F. Gaita b,c, R. Bonamini b
aKing’s College London, Wellcome Trust/EPSRC Medical Engineering Centre, Division of Imaging Sciences, St Thomas’
Hospital, UK
bDepartment of Internal Medicine, University of Torino, Italy
cDivision of Cardiology, Cardinal Massaia Hospital, University of Torino, Asti, Italy
dDivision of Cardiology, A.O. Ordine Mauriziano di Torino Presidio Umberto I, Torino, Italy
eDepartment of Cardiology, Santa Corona Hospital, Pietra Ligure, Italy
fDepartment of Radiology, Cardinal Massaia Hospital, Asti, Italyarticle information
Article history:
Received 7 October 2014
Received in revised form
16 December 2014
Accepted 29 December 2014* Guarantor and correspondent: A. Chiribiri, Div
Lambeth Wing, St Thomas’ Hospital, London SE1
E-mail address: amedeo.chiribiri@kcl.ac.uk (A
http://dx.doi.org/10.1016/j.crad.2014.12.018
0009-9260/ 2015 The Royal College of Radiologists.
by/4.0/).AIM: To measure the prevalence of abnormal rest perfusion in a population of consecutive
patients with known hypertrophic cardiomyopathy (HCM) referred for cardiovascular MRI
(CMR), and to assess any associations between abnormal rest perfusion and the presence,
pattern, and severity of myocardial scar and the presence of risk factors for sudden death.
MATERIALS AND METHODS: Eighty consecutive patients with known HCM referred for CMR
underwent functional imaging, rest ﬁrst-pass perfusion, and late gadolinium enhancement
(LGE).
RESULTS: Thirty percent of the patients had abnormal rest perfusion, all of them corresponding
to areas of mid-myocardial LGE and to a higher degree of segmental hypertrophy. Rest perfusion
abnormalities correlated with more extensive and conﬂuent LGE. The subgroup of patients with
myocardial ﬁbrosis and rest perfusion abnormalities (ﬁbrosisþ/perfusionþ) had more than twice
the incidence of episodes of non-sustained ventricular tachycardia on Holter monitoring in
comparison to patients withmyocardialﬁbrosis and normal rest perfusion (ﬁbrosisþ/perfusione)
and patients with no ﬁbrosis and normal rest perfusion (ﬁbrosise/perfusione).
CONCLUSIONS: First-pass perfusion CMR identiﬁes abnormal rest perfusion in a signiﬁcant
proportion of patients with HCM. These abnormalities are associated with the presence and
distribution of myocardial scar and the degree of hypertrophy. Rest perfusion abnormalities
identify patients with increased incidence of episodes of non-sustained ventricular tachycardia
on Holter monitoring, independently from the presence of myocardial ﬁbrosis.
 2015 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).ision of Imaging Sciences and Biomedical Engineering, King’s College London, The Rayne Institute, 4th Floor
7EH, UK. Tel.: þ44 20 7188 7242; fax: þ44 20 7188 5442.
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Sudden cardiac death (SCD) and progressive left ventric-
ular (LV) impairment are complications associated with hy-
pertrophic cardiomyopathy (HCM).1 Interstitial ﬁbrosis and
scarring are linked with progressive LV dysfunction and are
associated with SCD. Also abnormalities of myocardial
perfusion are of importance in the pathophysiology of the
disease. A few studies have used cardiovascularMRI (CMR) to
describe LV perfusion abnormalities in patients with HCM,
during adenosine stress2,3 or at rest.4e6 Abnormal stress
perfusion has been related to the presence of microvascular
disease. Conversely, abnormal rest perfusion has been con-
nected to the degree of hypertrophy and the extent of ﬁbrosis
detected with late gadolinium enhancement (LGE).
The aims of the present study were to measure the
prevalence of abnormal rest perfusion in a population of
patients with HCM referred for CMR, and to deﬁne the
relationship between rest perfusion abnormalities and the
extent and pattern of LGE and the presence of risk factors
for sudden death.
Materials and methods
This multicentre study involved 80 consecutive patients
with HCM referred for CMR from dedicated HCM clinics at
the Ospedale di Rivoli (Rivoli, Torino, Italy; n ¼ 56) and at
the Ospedale Cardinal Massaia (Asti, Italy; n ¼ 24) on the
date of their yearly routine clinical follow-up. Patients with
contraindications to CMR or history of anaphylactic re-
actions and patients with atrial ﬁbrillation were excluded.
Risk stratiﬁcation
Four risk factors were used to stratify patients’ risk for
SCD: family history of HCM-related premature SCD, unex-
plained syncope, presence of severe LV hypertrophy
(30 mm) and episodes of non-sustained ventricular
tachycardia (NSVT) evaluated on an ECG-Holter performed
on the enrolment visit (1 month before the CMR examina-
tion). Echocardiographic parameters were considered from
the most recent available examination.
Image acquisition
CMR was performed according to standard protocols7,8
using a 1.5 T system (Siemens Avanto, Erlangen, Germany)
with fast gradients (45 mT/m; 200 T/m/s slew-rate), using a
12-element cardiac phased-array coil and cardiac package
(Siemens Syngo-VB13, Erlangen, Germany). Steady-state
free precession loops [repetition time (TR) 3.6 ms, echo time
(TE) 1.8 ms, ﬂip angle 65, 30 acquired cardiac phases,
typical voxel size after adapting the ﬁeld of view to the
anatomy of the chest of the patient 1.7  1.4  8 mm] were
acquired in LV long-axis and short-axis views for LV mass
and function measurements.
First-pass perfusion imaging was performed during in-
jection of a gadolinium contrast agent (gadobutrol;
Gadovist, Schering AG, Berlin, Germany) at a dose of0.1 mmol/kg of body weight of gadolinium administered
with a power injector (Medrad Spectris Solaris, Medrad
Europe BV, Maastricht, The Netherlands) at a rate of 5 ml/s,
followed by 20 ml saline. Perfusion images were acquired
using a saturation-recovery sequence (prepulse delay
100 ms; turbo fast low-angle shot) with an acquisition
time of 172 ms per section, TR 1.5 ms, TE 0.99 ms, ﬂip angle
12, typical voxel size after adapting the ﬁeld of view
1.7  2.6  10 mm. Perfusion series were acquired in three
short-axis views covering the basal, mid-ventricular and
apical segments and additionally in a four-chamber long-
axis view when heart rate allowed it. The minimum
duration of acquisition of the perfusion sequence was
1 min, corresponding to 45e90 dynamics depending on
rest heart rate. Free breathing was permitted after ﬁrst
passage of the contrast agent and the remaining dose was
administered after the completion of the perfusion
sequence (up to a total of 0.2 mmol/kg of body weight).
LGE was performed approximately 20 min after the second
injection using an inversion-recovery spoiled gradient-
echo sequence (TR 2.4 ms, TE 0.96 ms, ﬂip angle 15,
typical voxel size after adapting the ﬁeld of view
1.8  1.3  8 mm).
Image analysis
All images were analysed using a workstation (Argus;
Siemens, Germany) by three of the authors whose joint
opinion was reached in consensus. Segmentation into 16
myocardial segments9 was used to describe the ﬁndings.
Wall thickness was measured in end-diastole at the point of
maximum thickness of each segment. Basal and mid-
ventricular segments were measured on short-axis views,
apical segments were measured in four- and two-chamber
long axis views, as appropriate. The endocardial and
epicardial border of the LV were traced in each short-axis
view in the end-diastolic and end-systolic frames, to mea-
sure LV global systolic function and LV mass. The area of the
atria was measured in end-systole in the four-chamber
views. Perfusion images were evaluated qualitatively by
visual inspection. Abnormal rest perfusion was deﬁned as a
reduced wash-in of the contrast agent in relation to other
parts of the myocardium, persisting for at least ﬁve heart-
beats.2 The distribution of the perfusion defects was
compared with the LV myocardial thickness and the dis-
tribution of LGE. LGE was evaluated visually (presence/
absence; number of LGE positive segments). The pattern of
LGE was scored according to Moon et al.10 Moreover, semi-
automated quantiﬁcation of LGE was performed according
to published methods.11e13 LGE volume was computed
based on a 5 SD threshold above the mean remote
myocardial signal13 using dedicated software (CVI 42
version 4, Circle Cardiovascular Imaging, Calgary, Alberta,
Canada).
Statistical analysis and ethics
Patients with abnormal rest perfusion were compared
with patients with normal rest perfusion for the presence of
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ings. Continuous data are presented as mean  SD; dichoto-
mous data are presented as numbers and percentages. The
KolmogoroveSmirnov test was used for distribution checks
of continuous variables. Differences in baseline characteris-
tics between groups were evaluated with unpaired Student’s
t-tests, ManneWhitney U-tests or Fisher’s exact tests as
appropriate. All tests were two sided, and a value of p < 0.05
was considered statistically signiﬁcant. The association be-
tween perfusion abnormalities and hypertrophy was
assessed with logistic regression. The association between
prevalence of abnormal rest perfusion and LGE, hypertrophy,
and the association between LGE and hypertrophy were
performed with mixed effects models. All statistical analyses
were carried out using the statistical software packages SAS
9.2 (SAS Institute, NC, USA) and SPSS v.19 (SPSS, Chicago, IL,
USA). This study complies with the Declaration of Helsinki
and was conducted according to the standards set by the
institutional ethics committee. No changes to the clinical
protocol in use for the evaluation of patients with HCMwere
needed to carry out the study; therefore, no formal approval
fromthe institutional ethics committeewas sought. Informed
consent was obtained from all patients.
Results
Abnormal rest perfusion was present in 24 patients
(30%), involving 62 segments (2.6 segments per-patient
among positives; range 1e10). Patients with normal and
abnormal rest perfusion were identical for most de-
mographics and echocardiographic characteristics after
indexing for body surface area (BSA; Table 1). Patients with
abnormal perfusion showed a higher indexed end-systolic
volume, although the difference of LV ejection fraction
was not signiﬁcant (Table 2). All areas with abnormal restTable 1
Characteristics, demographics, and risk factors for sudden cardiac death of the stu
perfusion.
All patient
(n ¼ 80)
Demographics
Age 49.8  18
Male sex 53 (70%)
Height, cm 169.4  10
Weight, kg 73.1  15
Body mass index, kg/m2 25.6  4
Body surface area, m2 1.9  0
New York Heart Association functional class 1.4  1
Echocardiographic parameters
Mitral regurgitation 36 (47%)
LV outﬂow tract obstruction 27 (35%)
Systolic anterior movement mitral valve 25 (33%)
Echocardiographic ejection fraction 57.3  19
Risk factors for sudden cardiac death
Family history of HCM-related sudden cardiac death, % 22.4
Syncope, % 11.8
Non-sustained ventricular tachycardia (Holter monitoring), % 22.4
Severe hypertrophy (>30 mm) 17.1%
Number of risk factors for sudden cardiac death 0.8  1
LV, left ventricular, HCM, hypertrophic cardiomyopathy.perfusion showed LGE (Fig 1) with mid-myocardial locali-
zation. None of the patients showed any perfusion defects
or LGE with patterns and distribution compatible with
coronary artery disease.
Comparison between perfusion and LGE
Sixty-four patients (80%) showed areas of LGE, with a
total of 270 positive segments (21.1%; 3.4  2.8 segments/
patient; range 0e12). LGE was present in all patients with
rest perfusion abnormalities and in 71% of those with
normal rest perfusion (p ¼ 0.003; Table 2). The prevalence
of LGE was associated with the distribution of hypertrophy
(p < 0.001) and with the prevalence of perfusion abnor-
malities (p < 0.001) in mixed-effects models.
Patients with abnormal rest perfusion presented with a
more extensive LGE in comparison with patients with
normal rest perfusion on both visual assessment (5.4  2.9
LGE positive segments, range 1e12 segments versus
2.6  2.3 segments, range 0e9 segments, respectively;
p ¼ 0.001; Table 2) and quantitative assessment (28%  17%
versus 14%12%, respectively; p ¼ 0.001; Table 2). Finally,
patients with abnormal rest perfusion showed a signiﬁ-
cantly higher prevalence of a conﬂuent pattern of LGE (75%
versus 38%; p ¼ 0.002; Table 2).
Comparison between perfusion and hypertrophy
The LV maximum thickness was 23  7 mm
(15e46 mm; patients with abnormal rest perfusion
16e40 mm; patients with normal rest perfusion
15e46 mm; p ¼ 0.19), with a total of 442 hypertrophic
segments of 1280 analysed (34.5%; 5.7  3 per patient).
The basal antero-septal segment showed the highest
average maximal thickness (20.1  7 mm), followed by thedy group and comparison between patients with abnormal and normal rest
s Group 1 (abnormal rest
perfusion, n ¼ 24)
Group 2 (normal rest
perfusion, n ¼ 56)
p-Value
45.9  16 51.3  18 0.250
18 (82%) 35 (65%) 0.176
174.1  10 167.5  9 0.010
77.7  11 71.1  16 0.082
25.6  3 25.6  5 0.926
1.9  0 1.8  0 0.018
1.4  1 1.3  1 0.834
11 (50%) 25 (46%) 0.443
11 (50%) 16 (30%) 0.102
9 (40%) 16 (30%) 0.601
56.3  20 57.7  18 0.782
13.6 25.9 0.364
9.1 13 1.000
40.9 14.8 0.030
22.7% 14.8% 0.504
0.9  1 0.7  1 0.470
Table 2
Cardiovascular MRI (CMR) measurements of the study group and comparison between patients with abnormal and normal rest perfusion.
All patients
(n ¼ 80)
Group 1 (abnormal rest
perfusion, n ¼ 24)
Group 2 (normal rest
perfusion, n ¼ 56)
p-Value
Left ventricular function and mass
Indexed left atrium (cm2/m2) 16  4 17  5 15  4 0.107
Indexed right atrium (cm2/m2) 12  3 12  2 11  3 0.218
Ejection fraction: left ventricle 58.6  9 55.4  10 59.9  9 0.069
Indexed stroke volume (ml/beat/m2) 45.4  8 45.4  8 45.3  8 0.920
Indexed end-diastolic volume: left ventricle (ml/m2) 79.1  15 84.6  16 77.0  15 0.070
Indexed end-systolic volume: left ventricle (ml/m2) 34.0  13 39.2  14 32.0  12 0.038
Indexed left ventricular wall mass (g/m2) 102.3  40 116.5  46 96.6  36 0.066
Maximum left ventricular myocardial thickness 23.0  7 24.6  7 22.4  7 0.194
Late gadolinium enhancement
Presence of ﬁbrosis 64 (80%) 24 (100%) 40 (71%) 0.003
Number of segments with ﬁbrosis 3.4  3 5.4  3 2.6  2 0.001
Fibrosis pattern 0.007
Conﬂuent 39 (49%) 18 (75%) 21 (38%) 0.002
Diffuse 14 (18%) 3 (13%) 11 (14%) 0.441
Mixed 11 (14%) 3 (13%) 8 (14%) 0.832
Fibrosis % volume (5 SD above mean of normal myocardium) 18  15 28  17 14  12 0.001
A. Chiribiri et al. / Clinical Radiology 70 (2015) 495e501498mid-ventricular infero-septal segment (18.5  7 mm) and
the anterior septum at mid-ventricular level
(17.3  8 mm). The localization of perfusion abnormalities
was associated with the degree of hypertrophy in a mixed-
effects model (p < 0.001).Figure 1 Findings in a 35-year-old patient with severe hypertrophy. (a
maximum hypertrophy (the short axis cine sequence shown (a) was acq
respondence with the areas of enhancement seen in (e). Perfusion images
abnormalities in short-axis (c) and long-axis (d), corresponding to areasPrevalence of risk factors for SCD
Seventeen patients (21%) had two or more risk factors for
SCD, 23 patients (29%) had one risk factor, and 40 patients
(50%) had no risk factors. The average number of risk factors) Short-axis and (b) long-axis images showing the segments with
uired soon after gadolinium injection, showing raised signal in cor-
at peak enhancement of normal myocardium, showing rest perfusion
of LGE (eef).
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perfusion was not different from the average of the popu-
lation (Table 1). An association was found between the
presence of rest perfusion abnormalities and the prevalence
of NSVT (p ¼ 0.03). No association was found between the
presence of rest perfusion abnormalities and any of the
other considered risk factors (Table 1).
A higher prevalence of NSVTwas also associated with the
presence of signiﬁcant hypertrophy (50% amongst patients
with maximum LV thickness >30 mm and 16% amongst the
others; p¼ 0.002) and with the volume of LGE both for 2 SD
and 5 SD (p ¼ 0.03 and p ¼ 0.022, respectively).
Fig 2 shows the percentage of patients with NSVT for
three different patient categories based on the presence of
scar tissue (ﬁbrosisþ/) in combination with abnormal rest
perfusion (perfusionþ/). Patients with ﬁbrosis and rest
perfusion abnormalities (ﬁbrosisþ/perfusionþ) showed a
prevalence of NSVT that was more than twice as high as in
patients showing ﬁbrosis with normal rest perfusion
(ﬁbrosisþ/perfusione; p ¼ 0.03) and in patients without
ﬁbrosis and without rest perfusion abnormalities
(ﬁbrosis/perfusion; p ¼ 0.04). Interestingly, no differ-
ence was found between patients with ﬁbrosis and normal
rest perfusion and patients without ﬁbrosis and without
rest perfusion abnormalities (p ¼ 1.000).Discussion
The main ﬁndings of the present study are that (1) rest
perfusion abnormalities are observed in 30% of patients
with HCM; (2) rest perfusion abnormalities correlate with
the severity of LGE and with the degree of hypertrophy; and
(3) abnormal rest perfusion identiﬁes a subgroup of pa-
tients with more advanced and clinically signiﬁcant ﬁbrosis.Figure 2 Percentage of patients with NSVT for three different groups
based on the presence of absence of ﬁbrosis (ﬁbrosisþ/ﬁbrosise) and
rest perfusion abnormalities (perfusionþ/perfusione).The high prevalence of LGE in patients with HCM has
been reported in many studies.11,12,14 LGE pattern and dis-
tribution also contribute to the differential diagnosis of
HCM from other cardiomyopathies.15,16 LGE is associated
with the degree of hypertrophy17,18 and has been associated
with the occurrence of ventricular arrhythmias,19,20 pro-
gressive ventricular dilatation, markers of SCD,10 with all-
cause and cardiac mortality,11 as well as with major car-
diovascular events, hospitalization, heart failure, and
arrhythmic events.12
In recent years, several authors have proposed the use of
either rest or stress perfusion CMR for the assessment of
patients with HCM. Matsunaka et al.4 was the ﬁrst to
describe a very high prevalence (75%) of rest perfusion ab-
normalities in a small selected population of 12 patients
with HCM and related its presence to the distribution of LGE
and the reduction of regional contractile function. The au-
thors hypothesized a relationship between abnormal rest
perfusion and the mechanical and anatomical effects of the
increase in extracellular water fraction and the reduction in
capillary density, respectively, observed in areas of LGE. In a
different study, Soler et al.6 related abnormal rest perfusion
(seenwith a prevalence of 30%) to an impairment of systolic
regional contraction. More recently, Melacini et al.5
demonstrated LGE and rest perfusion abnormalities in 46%
of patients with HCM.
In the present study, abnormal rest perfusion was found
in 30% of patients, in accordance with previous studies. To
the authors’ knowledge, the present study enrolled the
largest population of patients so far. All perfusion abnor-
malities in the present cohort were spatially associatedwith
regions of LGE. Perfusion defects were mostly associated
with areas of conﬂuent LGE. This likely represents an
extreme degree of microvascular remodelling in areas of
more dense scar,21,22 resulting in a slower inﬂow of contrast
agent during ﬁrst-pass.23 Accordingly, more severe ﬁbrosis
relates to more pronounced microvascular remodelling and
to a higher probability of rest perfusion abnormalities.
Quantitative LGE analysis for 5 SD threshold conﬁrmed the
signiﬁcant correlation between rest perfusion abnormal-
ities and volume of LGE. Therefore, based on the present
results, rest perfusion abnormalities should not be consid-
ered an expression of myocardial ischaemia but rather a
marker of severe myocardial ﬁbrosis.
Although the present study focused on rest perfusion
abnormalities, adenosine-induced perfusion abnormalities
have also been reported in the literature.2,3 These are
considered instead a marker of microvascular dysfunction
and have also been associated in previous studies with the
degree of hypertrophy. However, adenosine-induced
perfusion abnormalities have a subendocardial localiza-
tion that does not resemble the distribution of LGE,2 prob-
ably indicating a different underlying pathophysiological
mechanism.
The possibility that severe myocardial ﬁbrosis can cause
perfusion abnormalities should, however, be considered
when adenosine stress perfusion imaging is prescribed in
patients with HCM to assess the LV ischaemic burden. Scar-
related perfusion abnormalities and adenosine-induced
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signiﬁcant proportion of patients. However, the true
ischaemic burden is likely to be better represented by
adenosine-induced perfusion defects, without considering
areas of abnormal perfusion correlated with severe
myocardial ﬁbrosis. Combined high-resolution quantiﬁca-
tion of stress perfusion and LV ﬁbrosis could in future
improve the assessment of patients with HCM and perhaps
even enable the use of perfusion as a novel independent
predictor of events.
Currently, risk stratiﬁcation schemes identify only a
limited proportion of patients at risk of SCD,1,24e28 which is
the most threatening expression of the disease. LGE has
been proposed as a method to improve risk stratiﬁcation
and CMR is being used in an increasing number of pa-
tients.29,30 However, the reported high prevalence of LGE
among patients with HCM and the relatively low incidence
of arrhythmic events at follow-up31 clearly delineates an
important overlap between groups of patients with
different degrees of myocardial damage and risk,32 under-
scoring the need to improve risk stratiﬁcation beyond the
mere presence or absence of LGE.33
The correlation between imaging ﬁndings and risk fac-
tors for SCD was examined in the present cohort popula-
tion. Patients with abnormal rest perfusion and LGE had
more than double the prevalence of NSVT when compared
with the group of patients showing LGE and normal rest
perfusion. The latter did not differ from the group of pa-
tients without LGE (Fig 2). As such, abnormalities of rest
perfusion could be a useful marker to identify those pa-
tients with more severe microvascular remodelling, and
severe and dense scarring. As rest perfusion examination is
an easily applicable, rapid, and reproducible technique, it is
feasible to obtain important information from its regular
application at the expense of a trivial time delay.
Study limitations
The present ﬁndings are based on a population of pa-
tients with a clinical proﬁle of loweintermediate risk. The
validity of these ﬁndings in a population of high-risk pa-
tients with HCM should be further evaluated. Quantitative
analysis of rest perfusion abnormalities was not performed
but visual assessment was performed; the perfusion
acquisition protocol was optimized for this purpose. A stress
perfusion study was also not performed.
In conclusion, ﬁrst-pass perfusion CMR can identify
abnormal rest perfusion in a signiﬁcant proportion of pa-
tients with HCM. These abnormalities are associated with
areas of severe ﬁbrosis and aremost likely due to a reduction
in thenumberof capillaries in areasof scar tissue. Adequately
powered prospective studies relating the CMR ﬁndings, and
in particular, the presence of rest perfusion abnormalities, to
risk stratiﬁcation would be needed in future.
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